Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0AUCH)

Drug Name

Reslizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Severe asthma	CA23	Approved	[1]
Eosinophilic asthma	CB02.0	Phase 3	[2]
Asthma	CA23	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-5 (IL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benralizumab	DM7P1J4	Asthma	CA23	Approved	[5]
Mepolizumab	DMW2GEJ	Severe asthma	CA23	Approved	[6]
GSK3511294	DMWKSFY	Asthma	CA23	Phase 3	[7]
Depemokimab	DMG9VHN	Asthma	CA23	Phase 3	[7]
SOPHORICOSIDE	DM4A0NP	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091).
3	ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
4	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
5	Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
6	Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
7	A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.
8	Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9.